Literature DB >> 29848034

Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening in the United States: Is It Time?

Melina B Flanagan1.   

Abstract

CONTEXT: - The most recent update to cervical cancer screening guidelines offers interim guidance on the use of primary human papillomavirus (HPV) screening, with algorithms for management of results. After decades of screening with pure cytology and a shorter time with adjunctive HPV or cotesting with Papanicolaou (Pap) test and HPV, this is a significant change to our screening methods.
OBJECTIVE: - To briefly review the history of cervical cancer screening, the evidence upon which these interim guidelines were based, the arguments for and against primary HPV testing, and the current state of the field. DATA SOURCES: - Primary studies, review articles, and commentaries were reviewed.
CONCLUSIONS: - While there is evidence both for and against primary HPV testing, there are a growing number of countries adopting the practice. It would be worthwhile to be informed and prepared for such a change in the United States as well.

Entities:  

Mesh:

Year:  2018        PMID: 29848034     DOI: 10.5858/arpa.2018-0001-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

1.  MiR-218 produces anti-tumor effects on cervical cancer cells in vitro.

Authors:  Li Zhu; Huaidong Tu; Yanmei Liang; Dihong Tang
Journal:  World J Surg Oncol       Date:  2018-10-12       Impact factor: 2.754

2.  Long Non-Coding RNA HULC Promotes Cervical Cancer Cell Proliferation, Migration and Invasion via miR-218/TPD52 Axis.

Authors:  Wenjun Lu; Xiaobin Wan; Limin Tao; Junhui Wan
Journal:  Onco Targets Ther       Date:  2020-02-05       Impact factor: 4.147

3.  The Utility of Urine-Based Sampling for Cervical Cancer Screening in Low-Resource Settings.

Authors:  Sasidharanpillai Sabeena; Santhosh Kuriakose; Damodaran Binesh; Jazeel Abdulmajeed; Giselle Dsouza; Amrutha Ramachandran; Bindu Vijaykumar; Sushama Aswathyraj; Santhosha Devadiga; Nagaraja Ravishankar; Govindakarnavar Arunkumar
Journal:  Asian Pac J Cancer Prev       Date:  2019-08-01

4.  The New Biomarker for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC) Based on Public Database Mining.

Authors:  Hao Ding; Xiao-Xing Xiong; Guan-Lan Fan; Yue-Xiong Yi; Yu-Rou Chen; Jing-Tao Wang; Wei Zhang
Journal:  Biomed Res Int       Date:  2020-04-12       Impact factor: 3.411

5.  Identification of Stemness-Related Genes for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma by Integrated Bioinformatics Analysis.

Authors:  Hongjun Guo; Siqiao Wang; Min Ju; Penghui Yan; Wenhuizi Sun; Zhenyu Li; Siyu Wu; Ruoyi Lin; Shuyuan Xian; Daoke Yang; Jun Wang; Zongqiang Huang
Journal:  Front Cell Dev Biol       Date:  2021-03-25

6.  The genetic variability, phylogeny and functional significance of E6, E7 and LCR in human papillomavirus type 52 isolates in Sichuan, China.

Authors:  Zhilin Song; Yanru Cui; Qiufu Li; Junhang Deng; Xianping Ding; Jiaoyu He; Yiran Liu; Zhuang Ju; Liyuan Fang
Journal:  Virol J       Date:  2021-05-03       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.